Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) received a new U.S. patent for Vafseo (vadadustat) with a term to January 18, 2043.
U.S. Patent No. 12,797,375 covers a method of treatment relating to the modulation of drug-drug interactions during vadadustat treatment. It is eligible for listing in the FDA's Orange Book, the agency's register of approved drugs and related patents. Fourteen other vadadustat patents are currently listed there, with expiration dates between 2027 and 2036.
Vafseo received FDA approval in March 2024 to treat anemia due to chronic kidney disease in adults who have received dialysis for at least three months. It has been available in the U.S. since January 2025. Akebia believes the additional patent enhances Vafseo's long-term value.
Positive
- Minor pointNew Vafseo method-of-treatment patent granted with a term to January 18, 2043; eligible for Orange Book listing.
Negative
- None.
Details
Market Reaction – AKBA
On Nov 17, the day this news came out, the latest delayed price for AKBA is 4.90% above the previous close. Our momentum scanner has recorded 43 alerts for this stock so far that day. The latest delayed price is $0.42.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- New patent term
- Through January 18, 2043
- Vadadustat method-of-treatment patent; eligible for Orange Book listing
- Other Orange Book patents
- 14 patents; expiration dates between 2027 and 2036
- Other vadadustat patents currently listed
Key Terms
orange book regulatory
hif-ph inhibitor medical
ckd medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New patent with term until 2043 further strengthens patent portfolio
WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted for Vafseo® (vadadustat), strengthening Akebia’s vadadustat intellectual property portfolio. The patent, issued by the United States Patent and Trademark Office (USPTO) on November 17, 2026, as U.S. Patent No. 12,797,375 is eligible for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and has a term to January 18, 2043.
“We are pleased to continue to build the vadadustat patent portfolio with this new patent that has a term to January 2043, and which we believe enhances the long-term value of Vafseo,” said John P. Butler, Chief Executive Officer of Akebia. “We believe Vafseo can become the standard of care for the treatment of anemia due to chronic kidney disease, supported by compelling clinical outcomes and strong intellectual property protection to position Vafseo competitively in the market for years to come.”
The newly issued patent is a method of treatment patent relating to the modulation of drug-drug interactions during treatment with vadadustat. Fourteen other vadadustat patents are currently listed in the Orange Book with expiration dates between 2027 and 2036.
In March 2024, Vafseo, an oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Vafseo has been available in the U.S. since January 2025 and there are no other oral HIF-PH inhibitors to treat anemia in the market or in development in the U.S.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
About Vafseo® (vadadustat) tablets
Vafseo® (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia. Vafseo is approved for use in 37 countries.
INDICATION
VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
Limitations of Use
- VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being.
- VAFSEO is not indicated for use:
- As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
- In patients with anemia due to CKD not on dialysis.
IMPORTANT SAFETY INFORMATION about VAFSEO (vadadustat) tablets
| WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS. VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE). Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels. No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks. Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. |
CONTRAINDICATIONS
- Known hypersensitivity to VAFSEO or any of its components
- Uncontrolled hypertension
WARNINGS AND PRECAUTIONS
- Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access
A rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis.
- Hepatotoxicity
Hepatocellular injury attributed to VAFSEO was reported in less than1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in1.8% ,1.8% , and0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease.
- Hypertension
Worsening of hypertension was reported in14% of VAFSEO and17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in2.7% of VAFSEO and3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed.
- Seizures
Seizures occurred in1.6% of VAFSEO and1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency.
- Gastrointestinal (GI) Erosion
Gastric or esophageal erosions occurred in6.4% of VAFSEO and5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in3.4% of VAFSEO and3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present.
- Serious Adverse Reactions in Patients with Anemia Due to CKD and Not on Dialysis
The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa.
- Malignancy
VAFSEO has not been studied and is not recommended in patients with active malignancies.
Malignancies were observed in2.2% of VAFSEO and3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies.
ADVERSE REACTIONS
- The most common adverse reactions (occurring at ≥
10% ) were hypertension and diarrhea.
DRUG INTERACTIONS
- Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron.
- Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders.
- BCRP substrates: Monitor for signs of substrate adverse reactions and consider dose reduction.
- Statins: Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg.
USE IN SPECIFIC POPULATIONS
- Pregnancy: May cause fetal harm. A pregnancy exposure registry is available to monitor outcomes in women exposed to VAFSEO during pregnancy. Report pregnancies to 1-844-445-3799.
- Lactation: Breastfeeding not recommended until two days after the final dose.
- Hepatic Impairment: Not recommended in patients with cirrhosis or active, acute liver disease.
Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide.
Forward-Looking Statements
Statements in this press release regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: Akebia’s expectations and beliefs about the strength of its Vafseo® (vadadustat intellectual property portfolio; Akebia’s beliefs that the new patent enhances the long-term value of Vafseo; Akebia’s beliefs that Vafseo can become the standard of care for the treatment of anemia due to chronic kidney disease; Akebia’s beliefs and expectations regarding the strength of its intellectual property protection and clinical outcomes for Vafseo and the extent to which the foregoing position Vafseo competitively in the market for years to come; and Akebia’s expectations regarding its ability to maintain its intellectual property protection through the respective expiration dates.
The terms "intend," "believe," “designed,” "plan," "goal," "potential," "anticipate,” "estimate," “target,” “predict,” "expect," "future," “may,” "will," "continue," “could,” derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the potential therapeutic benefits, safety profile, and effectiveness of Vafseo and Akebia’s development candidates; risks and uncertainties related to Akebia's ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials, and the timing of such preclinical studies and clinical trials; the results of Akebia’s preclinical studies and clinical trials, including that initial, preliminary, interim, or topline results do not necessarily predict final results and remain subject to final verification that may result in the final data being materially different from the initial data previously published; preclinical, clinical or retrospective data, analyses or results may not be replicated in, or predictive of, results of future preclinical or clinical data, analyses or results or that such analyses or results may not support further development of such product candidates; Akebia’s ability to initiate and enroll patients in its clinical trials; decisions made by health authorities, such as the FDA, with respect to regulatory filings and other interactions; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to Akebia’s commercial products, including estimates regarding the potential market opportunity; the competitive landscape for Akebia’s commercial products, including generic entrants and the timing thereof; Akebia’s ability to obtain and maintain patent protection on its products and product candidates, and to successfully defend these patents against third-party challenges; Akebia's ability to attract and retain qualified personnel; Akebia's ability to achieve and maintain profitability and to maintain operating expenses consistent with its operating plan; Akebia's revenue and that its financial results from prior periods may not be indicative of future results; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; early termination of any of Akebia's collaborations; and changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs. Those and other risks and uncertainties are described in greater detail under the heading "Risk Factors" in Akebia's most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC), and other filings that Akebia may make with the SEC in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.
Akebia Therapeutics® and Vafseo® are registered trademarks of Akebia Therapeutics, Inc. and its affiliates.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Akebia's new Vafseo patent expire?
Akebia's newly granted Vafseo patent has a term to January 18, 2043. U.S. Patent No. 12,797,375 is eligible for Orange Book listing; fourteen other vadadustat patents are already listed, with expiration dates between 2027 and 2036.
What does Akebia's new Vafseo patent cover?
The new patent covers a method of treatment relating to the modulation of drug-drug interactions during treatment with vadadustat, the drug marketed as Vafseo.